Thermo Fisher Scientific Acquires Affymetrix

Thermo Fisher Scientific Acquires Brammer Bio for $1.7 Billion

March 25, 2019

Biotechnology

Thermo Fisher Scientific agreed to acquire Brammer Bio, a viral vector CDMO focused on gene and cell therapies, for approximately $1.7 billion in cash. The deal expands Thermo Fisher’s pharma services and viral vector manufacturing capabilities to support high-growth gene and cell therapy markets and brings a team of nearly 600 employees into its pharma services business.

Thermo Fisher Scientific Acquires Olink Holding AB

July 10, 2024

Biotechnology

Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.

Bruker Corporation Acquires PhenomeX Inc.

August 17, 2023

Biotechnology

Bruker Corporation agreed to acquire PhenomeX Inc. in an all-cash transaction valued at roughly $108 million (purchase price $1.00 per share). PhenomeX — formed from the combination of Berkeley Lights and IsoPlexis and provider of single-cell biology instruments, software and reagents — will be folded into a Bruker subsidiary, marking Bruker’s entry into single-cell biology research tools and complementing its spatial biology offerings.

Thermo Fisher Scientific Acquires MarqMetrix

June 21, 2023

Medical Devices

Thermo Fisher Scientific has completed its acquisition of MarqMetrix, a Seattle-based developer of Raman-based in-line spectroscopy and Process Analytical Technology (PAT). The deal adds Raman-based in-line PAT capabilities to Thermo Fisher’s Analytical Instruments segment; terms were not disclosed.

Thermo Fisher Scientific Acquires PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed the acquisition of PPD, Inc. for $17.4 billion in cash, plus the assumption of approximately $3.0–$3.5 billion of net debt. The deal brings PPD's global clinical research and laboratory services into Thermo Fisher's Laboratory Products and Services segment, expanding Thermo Fisher's capabilities in clinical development and expected to generate approximately $125 million of synergies by year three.

Thermo Fisher Scientific Acquires The Binding Site Group

October 31, 2022

Medical Devices

Thermo Fisher Scientific has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital for £2.25 billion (about $2.6 billion). The Binding Site, a Birmingham-based specialist in protein and blood-cancer diagnostics with more than 1,100 employees and ~10% annual revenue growth, will join Thermo Fisher's Specialty Diagnostics segment to expand its capabilities in cancer diagnostics and monitoring.